Increase in the oxidised low-density lipoprotein level by smoking and the possible inhibitory effect of statin therapy in patients with cardiovascular disease: A retrospective study

BMJ Open

Volumn 5, Issue 1, 2015, Pages

  Ogawa, Kazuo ^a   Tanaka, Toshikazu ^a   Nagoshi, Tomohisa ^a   Sekiyama, Hiroshi ^a   Arase, Satoshi ^a   Minai, Kosuke ^a   Ogawa, Takayuki ^a   Yoshimura, Michihiro ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SECONDARY HEALTH CARE; SMOKING; BLOOD; CORONARY ARTERY DISEASE; DRUG EFFECTS; MIDDLE AGED;

CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SMOKING;

EID: 84921752852     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005455     Document Type: Article

References (26)

1. Kotani K, Maekawa M, Kanno T, et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1994;1215:121-5.
2. Kitano S, Kanno T, Maekawa M, et al. Improved method for the immunological detection of malondialdehyde-modified low-density lipoproteins in human serum. Anal Chim Acta 2004;509:229-35.
3. Kondo A, Manabe M, Saito K, et al. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb 2002;9:280-7.
4. Kondo A, Muranaka Y, Ohta I, et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem 2001;47:893-900.
5. Kondo A, Li J, Manabe M, et al. Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations. J Atheroscler Thromb 2003;10:72-8.
6. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002;22:662-6.
7. Shigematsu S, Takahashi N, Hara M, et al. Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circulation J2007;71:1697-702.
8. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004;109:3164-70.
9. Yagi H, Komukai K, Hashimoto K, et al. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol 2010;55:345-53.
10. Sekiyama H, Nagoshi T, Komukai K, et al. Transient decrease in serum potassium level during ischemic attack of acute coronary syndrome: paradoxical contribution of plasma glucose level and glycohemoglobin. Cardiovasc Diabetol 2013;12:4.
11. Brinkman GL, Coates EO Jr. The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis 1963;87:684-93.
12. Yokode M, Kita T, Arai H, et al. Cholesteryl ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extract. Proc Natl Acad Sci USA 1988;85:2344-8.
13. Harats D, Ben-Naim M, Dabach Y, et al. Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages. Atherosclerosis 1989;79:245-52.
14. Gotto AM Jr. Interactions of the major risk factors for coronary heart disease. Am J Med 1986;80:48-55.
15. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317:1303-9.
16. Stein Y, Harats D, Stein O. Why is smoking a major risk factor for coronary heart disease in hyperlipidemic subjects? Ann N Y Acad Sci 1993;686:66-9.
17. Asano M, Ohkubo C, Hirokawa A, et al. Smoking Research Foundation Annual Research Report, on macro- and microcirculatory effects of tobacco smoke inhalation on atherogenesis in the rabbit. 1987:251-61.
18. Anderson KM, Wilson PW, Odell PM, et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
19. Holbrook JH, Grundy SM, Hennekens CH, et al. Cigarette smoking and cardiovascular diseases. A statement for health professionals by a task force appointed by the steering committee of the American Heart Association. Circulation 1984;70:1114a-17a.
20. Caralis DG, Deligonul U, Kern MJ, et al. Smoking is a risk factor for coronary spasm in young women. Circulation 1992;85:905-9.
21. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993;87:76-9.
22. Yoshimura M, Yasue H, Nakayama M, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998;103:65-9.
23. Nakayama M, Yasue H, Yoshimura M, et al. T-786->C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864-70.
24. Takaoka K, Yoshimura M, Ogawa H, et al. Comparison of the risk factors for coronary artery spasm with those for organic stenosis in a Japanese population: role of cigarette smoking. Int J Cardiol 2000;72:121-6.
25. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol 2008;51:1742-8.
26. Matsuda M, Tamura R, Kanno K, et al. Impact of dyslipidemic components of metabolic syndrome, adiponectin levels, and anti-diabetes medications on malondialdehyde-modified low-density lipoprotein levels in statin-treated diabetes patients with coronary artery disease. Diabetol Metab Syndr 2013; 5:77.